At ICON we have built our reputation on enduring partnerships that are driven to advance medicine and make a difference in the world. Since our inception in 1990 we’ve strived to work as a ‘trusted partner’ to our clients, collaborating, innovating and finding new ways together to improve outcomes. It’s been the lifeblood of our business and the vision that has shaped our strategy more than any other.
Providing full-service drug and device development, we understand the goals, issues and needs of our clients, we study their context, market and therapeutic area. We listen, ask questions and define the problems so that we know their pipeline, pressures and corporate objectives.
This is how we work, we don’t leave anything to chance, we know our clients and we own their goals.
Innovation at ICON is focused on the factors that are critical to our clients. Our overarching goal is simple; rapid access to, and analysis of, high-quality data to speed up and improve decision-making.
We adopt an integrated approach to identify common drug development problems, leverage process improvement in technology to tackle them and focus on core milestones to measure the impact.
Once proven, we build these innovations into our standard practice and tailor our delivery to meet our customer needs.
Our partnerships stand for nothing unless we deliver. 92% of our trials are ahead of schedule and on, or under, budget.
We have set our ambition to be over 20% better than industry benchmarks for our client milestones and outcomes. We track ourselves against these benchmarks and are transparent in sharing our performance.
In recognition of our accomplishments in driving efficiency in drug development, ICON has won a number of industry awards including The Scrip Best CRO Award, Best Vaccines CRO, PharmaTimes Best Partnership in Clinical Research, and PharmaTimes Clinical Researcher of the Year.